Rituximab-induced serum sickness: A systematic review

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 3, 2015, Pages 334-340

  Karmacharya, Paras ^a   Poudel, Dilli Ram ^a   Pathak, Ranjan ^a   Donato, Anthony A ^a   Ghimire, Sushil ^a   Giri, Smith ^b   Aryal, Madan Raj ^a   Bingham, Clifton O ^c  

^a Reading Health System   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infusion reaction; Rheumatoid arthritis; Rituximab; Serum sickness

Indexed keywords

ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; DIPHENHYDRAMINE; HYDROXYCHLOROQUINE; METHOTREXATE; PARACETAMOL; RHEUMATOID FACTOR; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADULT; ANGIONEUROTIC EDEMA; ARTHRALGIA; AUTOIMMUNE DISEASE; CASE REPORT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; INFUSION RELATED REACTION; MACULOPAPULAR RASH; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RIGOR; SERUM SICKNESS; SJOEGREN SYNDROME; SYNOVITIS; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; RITUXIMAB; SERUM SICKNESS;

EID: 84955702601     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.06.014     Document Type: Review

References (32)

1. Mok C.C. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 2013, 8:87-100.
2. Disperati P., Hicks L.K., Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma 2007, 48:1633-1635.
3. Portlock C.S., O'Connor O.A., Straus D.J., Rosenzweig L., Dumitrescu O., Lin O., et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. Leuk Lymphoma 2006, 47:1260-1264.
4. Todd D.J., Helfgott S.M. Serum sickness following treatment with rituximab. J Rheumatol 2007, 34:430-433.
5. DeMonaco N.A., Jacobs S.A. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med 2007, 32:933-934.
6. Harrold L.R., Reed G.W., Shewade A., Magner R., Saunders K.C., John A., et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA Registry. J Rheumatol 2015, 42:1090-1098.
7. Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaître O., Cohen P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014, 371:1771-1780.
8. Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013, 369:417-427.
9. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
10. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544.
11. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007, 57:310-317.
12. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007, 66:351-357.
13. Le Guenno G., Ruivard M., Charra L., Philippe P. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura. Intern Med J 2011, 41:202-205.
14. Goto S., Goto H., Tanoshima R., Kato H., Takahashi H., Sekiguchi O., et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009, 89:305-309.
15. Wang J., Wiley J.M., Luddy R., Greenberg J., Feuerstein M.A., Bussel J.B. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005, 146:217-221.
16. Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006, 107:2639-2642.
17. Godeau B., Porcher R., Fain O., Lefrère F., Fenaux P., Cheze S., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
18. Medeot M., Zaja F., Vianelli N., Battista M., Baccarani M., Patriarca F., et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 2008, 81:165-169.
19. Kumar A., Khamkar K., Gopal H. Serum sickness and severe angioedema following rituximab therapy in RA. Int J Rheum Dis 2012, 15:e6-e7.
20. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002, 70:329.
21. Hellerstedt B., Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003, 14:1792.
22. Finger E., Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007, 13:94-95.
23. Sène D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P. Rituximab may form a complex with IgMκ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
24. Catuogno M., Rezai S., Priori R., Magrini L., Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology 2005, 44:406.
25. D'Arcy C.A., Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001, 44:1717-1718.
26. Mehsen N., Yvon C.M., Richez C., Schaeverbeke T. Serum sickness following a first rituximab infusion with no recurrence after the second one. Clin Exp Rheumatol 2008, 26:967.
27. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
28. Sandhu A., Harford A., Singh P., Alas E. Is thymoglobulin or rituximab the cause of this serum sickness? A case report of serum sickness dilemma and literature review. Case Rep Med 2012, 2012:234515.
29. Schutgens R.E. Rituximab-induced serum sickness. Br J Haematol 2006, 135:147.
30. Ungprasert P., Srivali N., Kittanamongkolchai W., Leeaphorn N., Griger D.T. Rituximab-induced serum sickness in overlapping syndrome between Sjögren syndrome and systemic lupus erythematosus. J Clin Rheumatol 2013, 19:360.
31. Portlock C.S., O'Connor O.A., Straus D.J., et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. Leuk Lymphoma 2006, 47:1260-1264.
32. Todd D.J., Helfgott S.M. Serum sickness following treatment with rituximab. J Rheumatol 2007, 34:430-433.